相似化合物
79651-64-2 36052-26-3 69142-64-9欧盟法规
ECHA物质C&L通报上下游产品
CAS号26893-72-1 6-乙酰氨基吡啶羧酸 | CAS号5327-33-3 2-乙酰氨基-6-甲基吡啶 | CAS号1824-81-3 2-氨基-6-甲基吡啶 | CAS号4684-94-0 6-氯吡啶-2-羧酸 | CAS号21190-87-4 6-溴-2-吡啶羧酸 | CAS号13538-41-5 6-氨基-2-吡啶甲酰胺 | CAS号443956-21-6 6-氨基-3,5-二溴吡啶甲酸甲酯 | CAS号178876-83-0 6-氨基-3-溴吡啶甲酸甲酯 | CAS号178876-82-9 5-溴-6-氨基吡啶-2-羧酸甲酯 | CAS号203321-86-2 ETHYL 6-((TERT-... | CAS号79651-64-2 2-氨基-6-吡啶甲醇 | CAS号69142-64-9 6-氨基吡啶-2-羧酸乙酯 | CAS号153140-16-0 2-氨基-6-(2-羧基乙基)吡啶 | CAS号36052-26-3 6-氨基吡啶甲酸甲酯 | CAS号332884-35-2 6-氨基吡啶-2-甲醛 | CAS号203321-83-9 (6-(羟甲基)吡啶-2-基)...合成工艺路线路线简述
- 合成目标产物 6-Aminopyridine-2-Carboxylic Acid 主要起始原料 6-Acetamidopicolinic Acid, 6-(Acetylamino)Pyridine-2-Carboxylic Acid
- (文献来源)合成步骤主要原料 6-Acetamidopicolinic Acid, 6-(Acetylamino)Pyridine-2-Carboxylic Acid
6-氯吡啶-2-羧酸置于氨体系中,用 甲醇 用作溶剂,78.0 °C,40.0 Kpa 条件下,反应 48.0H,以59.2%的收率获得6-氨基-2-吡啶甲酸
参考文献:一种6-氨基-2-吡啶甲酸的制备方法
标题:一种6-氨基-2-吡啶甲酸的制备方法
摘要:本发明涉及有机合成技术领域,特别涉及一种6‑氨基‑2‑吡啶甲酸的制备方法,本发明是以2‑甲基‑6‑氯吡啶,高锰酸钾和氨甲醇为原料,进行氧化,氨解等反应后,进行纯化处理,得到了高纯度的6‑氨基‑2‑吡啶甲酸,本发明提供的合成6‑氨基‑2‑吡啶甲酸的方法,对设备要求低,整个过程操作简单,路线短,副产物少,腐蚀性低,环境污染小,易于工业化生产的合成方法,最后得到的产品结构稳定,含量较高.
海关参考信息
- 2905110000-甲醇
2912110000-甲醛
2915110000-甲酸
2933310010-吡啶 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12384788-B2
优先权日:2019-09-13
标 题 :1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease
发明人:KOESTLER ROLAND; TASSEL JEAN; THORMANN MICHAEL; YEHIA NASSER; TREML ANDREAS; ALMSTETTER MICHAEL
权利人:ORIGENIS GMBH
摘要:The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for treating diseases, such as autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, Alzheimer's disease, Parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 40 to 146; examples 1 to 63; compounds 1 to 248; tables 1 to 3). Preferred compounds are e.g. 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds. An exemplary compound is e.g. 5-(2,6-difluorophenyl)-8-methoxy-1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine (example 49). (Formula (II):
专利号:US-7169932-B2
优先权日:2001-06-11
标题:HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
发明人:KUCERA DAVID JOHN; SCOTT ROBERT WILLIAM
权利人:PFIZER
摘要:Compounds of the formula: n nwhere the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
专利号:US-5403845-A
优先权日:1991-08-27
标 题:Muscarinic agonists
发明人:DUNBAR PHILIP G; DURANT GRAHAM J; HOSS WAYNE P; MESSER JR WILLIAM S
权利人:UNIV TOLEDO
摘要:Substituted 1,4,5,6 -tetrahydropyrimidine compositions, substituted 1,2,3,6 -tetrahydropyrimidine compositions and substituted 3,4,5,6 -tetrahydropyridine compositions are disclosed. They are useful for stimulating muscarinic receptors including, for example, treating the symptoms of cognitive disorders, especially impaired memory, which are associated with decreased acetylcholine synthesis and cholinergic cell degeneration.